Piedmont Investment Advisors’s Emergent Biosolutions EBS Stock Holding History

Piedmont Investment Advisors’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-11,423	Closed	-$577K	–	1024
2019 Q1	$577K	Buy	11,423 +642	+6%	+$37.9K	0.02%	461
2018 Q4	$639K	Buy	10,781 +531	+5%	+$34.2K	0.03%	376
2018 Q3	$675K	Buy	10,250 +1,748	+21%	+$102K	0.03%	402
2018 Q2	$429K	Buy	8,502 +904	+12%	+$47.1K	0.02%	497
2018 Q1	$400K	Buy	7,598 +264	+4%	+$13.2K	0.01%	474
2017 Q4	$341K	Sell	7,334 -397	-5%	-$16.7K	0.01%	519
2017 Q3	$313K	Buy	7,731 +204	+3%	+$7.38K	0.01%	555
2017 Q2	$255K	Buy	+7,527	New	+$232K	0.01%	618

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Piedmont Investment Advisors's EBS Position: Q2 2019 in Review

Piedmont Investment Advisors sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 11,423 shares — an estimated $577K sold.

Piedmont Investment Advisors first reported a position in EBS in Q2 2017 and held it in 8 quarters. The position peaked at $675K in Q3 2018. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

Piedmont Investment Advisors reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
Piedmont Investment Advisors sold 11,423 Emergent Biosolutions shares in Q2 2019, an estimated $577K.
Piedmont Investment Advisors first reported a position in Emergent Biosolutions in Q2 2017 and held it in 8 quarters.
Piedmont Investment Advisors's Emergent Biosolutions position peaked at $675K in Q3 2018.
233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Piedmont Investment Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.